Access the full text.
Sign up today, get DeepDyve free for 14 days.
Poulikos Poulikakos, Yogindra Persaud, M. Janakiraman, X. Kong, Charles Ng, G. Moriceau, Hubing Shi, M. Atefi, B. Titz, M. Gabay, M. Salton, K. Dahlman, M. Tadi, J. Wargo, K. Flaherty, M. Kelley, T. Misteli, P. Chapman, J. Sosman, T. Graeber, A. Ribas, R. Lo, N. Rosen, D. Solit (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 480
J. Lutzky, J. Bauer, B. Bastian (2008)
Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationPigment Cell & Melanoma Research, 21
P. LoRusso, A. Adjei, M. Varterasian, S. Gadgeel, J. Reid, D. Mitchell, L. Hanson, P. Deluca, L. Bruzek, J. Piens, Peggy Asbury, Keri Becelaere, R. Herrera, J. Sebolt-Leopold, M. Meyer (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 23
M. Garnett, R. Marais (2004)
Guilty as charged: B-RAF is a human oncogene.Cancer cell, 6 4
Jill Stahl, Arati Sharma, M. Cheung, M. Zimmerman, J. Cheng, M. Bosenberg, M. Kester, L. Sandirasegarane, G. Robertson (2004)
Deregulated Akt3 Activity Promotes Development of Malignant MelanomaCancer Research, 64
M. Atkins, L. Kunkel, L. Kunkel, M. Sznol, S. Rosenberg (2000)
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.The cancer journal from Scientific American, 6 Suppl 1
J. Wisell (2013)
Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaYearbook of Pathology and Laboratory Medicine, 2013
K. Flaherty, I. Puzanov, Kevin Kim, A. Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard Lee, J. Grippo, K. Nolop, P. Chapman (2010)
Inhibition of mutated, activated BRAF in metastatic melanoma.The New England journal of medicine, 363 9
(2008)
therapy for melanoma: a primer
J. Wilmott, G. Long, J. Howle, L. Haydu, Raghwa Sharma, J. Thompson, R. Kefford, P. Hersey, R. Scolyer (2011)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic MelanomaClinical Cancer Research, 18
K. Smalley, Keith Flaherty (2009)
Integrating BRAF/MEK inhibitors into combination therapy for melanomaBritish Journal of Cancer, 100
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.The New England journal of medicine, 364 26
A. Birck, V. Ahrenkiel, Jesper Zeuthen, Klaus Hou-Jensen, Per Guldberg (2000)
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.The Journal of investigative dermatology, 114 2
(2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast
S. Mocellin, S. Pasquali, C. Rossi, D. Nitti (2010)
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.Journal of the National Cancer Institute, 102 7
R. Nazarian, Hubing Shi, Qi Wang, X. Kong, R. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, N. Attar, H. Sazegar, T. Chodon, S. Nelson, G. McArthur, J. Sosman, A. Ribas, R. Lo (2010)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 468
P. Ascierto, C. Berking, S. Agarwala, D. Schadendorf, Carla Herpen, P. Queirolo, C. Blank, A. Hauschild, J. Beck, A. Zubel, F. Niazi, Simon Wandel, R. Dummer (2012)
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.Journal of Clinical Oncology, 30
D. Solit, L. Garraway, C. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, Jose Lobo, Y. She, I. Osman, T. Golub, J. Sebolt-Leopold, W. Sellers, N. Rosen (2006)
BRAF mutation predicts sensitivity to MEK inhibitionNature, 439
J. Sosman, Kevin Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas Hutson, S. Moschos, K. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. Lewis, R. Amaravadi, B. Chmielowski, H. Lawrence, Y. Shyr, Fei Ye, Jiang Li, K. Nolop, Richard Lee, A. Joe, A. Ribas (2012)
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.The New England journal of medicine, 366 8
K. Flaherty, J. Schiller, L. Schuchter, Glenn Liu, D. Tuveson, M. Redlinger, C. Lathia, C. Xia, O. Petrenciuc, S. Hingorani, Michael Jacobetz, P. Belle, D. Elder, M. Brose, B. Weber, M. Albertini, P. O'dwyer (2008)
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and PaclitaxelClinical Cancer Research, 14
A. Eggermont, S. Suciu, M. Santinami, A. Testori, W. Kruit, J. Marsden, C. Punt, F. Sales, M. Gore, R. MacKie, Z. Kusic, R. Dummer, A. Hauschild, E. Mușat, A. Spatz, U. Keilholz (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialThe Lancet, 372
J. Rinehart, A. Adjei, P. LoRusso, D. Waterhouse, J. Hecht, R. Natale, O. Hamid, M. Varterasian, Peggy Asbury, E. Kaldjian, S. Gulyas, D. Mitchell, R. Herrera, J. Sebolt-Leopold, M. Meyer (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 22
J. Curtin, K. Busam, D. Pinkel, B. Bastian (2006)
Somatic activation of KIT in distinct subtypes of melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 26
(2010)
interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.The New England journal of medicine, 366 26
A. Hauschild, S. Agarwala, U. Trefzer, D. Hogg, C. Robert, P. Hersey, A. Eggermont, S. Grabbe, R. Gonzalez, J. Gille, C. Peschel, D. Schadendorf, C. Garbe, S. O'Day, A. Daud, J. White, C. Xia, K. Patel, J. Kirkwood, U. Keilholz (2009)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 17
S. Wilhelm, Christopher Carter, L. Tang, D. Wilkie, Angela Mcnabola, H. Rong, Charles Chen, Xiaomei Zhang, P. Vincent, M. McHugh, Yichen Cao, Jaleel Shujath, S. Gawlak, Deepa Eveleigh, B. Rowley, Li Liu, Lila Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. Post, G. Bollag, P. Trail (2004)
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 64
F. Hodi, P. Friedlander, C. Corless, M. Heinrich, S. Rae, A. Kruse, J. Jagannathan, A. Abbeele, E. Velazquez, G. Demetri, David Fisher (2008)
Major response to imatinib mesylate in KIT-mutated melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 12
A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. Blank, B. Mirakhur, Mary Guckert, R. Swann, P. Haney, Anne-Marie Martin, D. Ouellet, K. Grotzinger, V. Goodman, P. Chapman (2012)
Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
M. Atkins, M. Middleton, P. Chapman (2009)
Chemotherapy-based treatment of metastatic melanoma
S. Heidorn, C. Milagre, S. Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, N. Dhomen, Jahan Hussain, J. Reis-Filho, C. Springer, C. Pritchard, R. Marais (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 140
(2011)
Phase II, open-label, singlearm trial of imatinib mesylate in patients
Alessia Russo, E. Torrisi, Y. Bevelacqua, R. Perrotta, M. Libra, J. McCubrey, D. Spandidos, F. Stivala, G. Malaponte (2009)
Melanoma: molecular pathogenesis and emerging target therapies (Review).International journal of oncology, 34 6
P. Chapman, A. Hauschild, C. Robert, J. Larkin, J. Haanen, A. Ribas, D. Hogg, O. Hamid, P. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. Sosman, C. Garbe, M. Maio, K. Nolop, B. Nelson, A. Joe, K. Flaherty, G. McArthur (2012)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma .Journal of Clinical Oncology, 30
Keith Flaherty, F. Hodi, Boris Bastian (2010)
Mutation-driven drug development in melanomaCurrent Opinion in Oncology, 22
V. Goel, Alexander Lazar, C. Warneke, M. Redston, F. Haluska (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.The Journal of investigative dermatology, 126 1
(2011)
mutated melanoma
J. Stockman (2013)
KIT as a Therapeutic Target in Metastatic MelanomaYearbook of Pediatrics, 2013
Jun Guo, L. Si, Y. Kong, K. Flaherty, Xiaowei Xu, Yanyan Zhu, C. Corless, Li Li, Haifu Li, X. Sheng, C. Cui, Z. Chi, Si-yuan Li, Mei Han, L. Mao, Xuede Lin, N. Du, Xiaoshi Zhang, Junling Li, Baocheng Wang, S. Qin (2011)
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 21
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
P. Ascierto, F. Marincola, A. Ribas (2011)
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationJournal of Translational Medicine, 9
J. Kirkwood, L. Bastholt, C. Robert, J. Sosman, J. Larkin, P. Hersey, M. Middleton, M. Cantarini, V. Zazulina, K. Kemsley, R. Dummer (2011)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced MelanomaClinical Cancer Research, 18
M. Davies, J. Gershenwald (2011)
Targeted therapy for melanoma: a primer.Surgical oncology clinics of North America, 20 1
P. Jänne, A. Shaw, J. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F. Franke, L. Grinsted, Paul Smith, V. Zazulina, I. Smith, L. Crinò (2012)
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 30
A. Ashida, M. Takata, H. Murata, K. Kido, T. Saida (2009)
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomasInternational Journal of Cancer, 124
K. Smalley, N. Haass, P. Brafford, Mercedes Lioni, K. Flaherty, M. Herlyn (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesMolecular Cancer Therapeutics, 5
(2011)
colon, and pancreatic cancer
K. Flaherty, M. Redlinger, L. Schuchter, C. Lathia, B. Weber, P. O'dwyer (2005)
Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanomaJournal of Clinical Oncology, 23
M. Gordon (2009)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialYearbook of Medicine, 2009
Paul Chapman, J. Haanen (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationYearbook of Surgery, 2012
Ipilimumab and vemurafenib have changed the clinical landscape in melanoma. Both drugs offer effective treatment for metastatic melanoma, but with limitations. Ipilimumab benefits only a minority of those treated, with no means to identify them prospectively. The efficacy of vemurafenib is tied to the presence of an activating mutation in BRAF, and so is more predictable. However, acquired resistance develops within months. As we understand these, and similar, agents better, the means to select patients for treatment, to increase the duration of response and to identify the best stage at which to intervene will lead to improved outcomes for patients. Several trials are already under way or being developed to build upon these exciting discoveries.
Therapeutic Advances in Medical Oncology – SAGE
Published: Oct 29, 2012
Keywords: clinical management,immunotherapy,melanoma,targeted therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.